'Prehabilitation' checklist for men with prostate cancer starting androgen deprivation therapy-Reference-Cited by-同舟云学术

'Prehabilitation' checklist for men with prostate cancer starting androgen deprivation therapy

Published:2024-03-21 Issue:3 Volume:15 Page:2-8
ISSN:2044-3730
Container-title:Trends in Urology & Men's Health
language:en
Short-container-title:Trends Urol & Men's Health

Author:

Payne Heather¹²,Bahl Amit³,Kirby Mike⁴⁵,Rees Jon⁶,Aning Jonathan⁷,Das Prantik⁸,Cornford Phil⁹,Bagnall Pauline¹⁰¹¹

Affiliation:

1. Prostate Centre London UK

2. University College London Hospitals UK

3. University Hospitals Bristol UK

4. Trends in Urology & Men's Health

5. The University of Hertfordshire Hatfield UK

6. Tyntesfield Medical Group, Nailsea UK

7. Bristol Urological Institute UK

8. University Hospitals of Derby and Burton NHS Foundation Trust UK

9. Liverpool University Hospitals NHS Foundation Trust UK

10. Northumbria Healthcare NHS Foundation Trust, North Tyneside UK

11. Prostate Cancer Research London UK

Abstract

Androgen deprivation therapy (ADT) plays an important, integral role in the treatment of prostate cancer; however, it is associated with multiple metabolic and other adverse effects. Making patients aware of these prior to starting ADT and assessing any specific risks during discussions is key to optimising outcomes. A brief checklist for health care professionals to use with patients, such as the one presented here, can aid discussions and facilitate signposting to appropriate specialist services without increasing workload.

Publisher

Wiley

Reference54 articles.

1. Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer

2. The Metabolic Syndrome and its Components in Patients with Prostate Cancer on Androgen Deprivation Therapy

3. Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer

4. Sexual Bother in Men with Advanced Prostate Cancer Undergoing Androgen Deprivation Therapy

5. Advanced Prostate Cancer Treated with Intermittent or Continuous Androgen Deprivation in the Randomised FinnProstate Study VII: Quality of Life and Adverse Effects